Published online before print June 22, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, Switzerland
1 Correspondence: Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, Wolfgang-Pauli-Str. 10, HCI H303, CH-8093 Zurich, Switzerland. E-mail: michael.detmar{at}pharma.ethz.ch
ABSTRACT
The extent of lymph node (LN) metastasis is a major determinant for the staging and the prognosis of most human malignancies and often guides therapeutic decisions. Although the clinical significance of LN involvement is well documented, little has been known about the molecular mechanisms that promote tumor spread via lymphatic vessels to sentinel and distal LN and beyond. However, recent discoveries have identified novel lymphatic-specific markers, and the newly discovered lymphangiogenesis factors vascular endothelial growth factor-C (VEGF-C) and VEGF-D were found to promote tumor-associated lymphatic vessel growth in mouse tumor models, leading to enhanced tumor spread to sentinel LN. Our recent findings indicate that VEGF-A also acts as a potent tumor lymphangiogenesis factor that promotes lymphatic tumor spread. VEGF-A overexpressing primary tumors induced sentinel LN lymphangiogenesis even before metastasizing and maintained their lymphangiogenic activity after metastasis to draining LN. Our recent studies showed that primary human melanomas that later metastasized were characterized by increased lymphangiogenesis and that the degree of tumor lymphangiogenesis can serve as a novel predictor of LN metastasis and overall patient survival, independently of tumor thickness. Tumor lymphangiogenesis also significantly predicted the presence of sentinel LN metastases at the time of surgical excision of the primary melanoma. Together, these findings suggest that tumor lymphangiogenesis actively contributes to cancer dissemination, that blockade of lymphatic vessel growth might inhibit tumor metastasis to LN, and that the extent of tumor-associated lymphangiogenesis could serve as a novel, prognostic parameter for the metastatic risk of human cancers.
Key Words: VEGF-A • VEGF-C
This article has been cited by other articles:
 |
|
 |
|
  T. Okazaki, A. Ni, O. A. Ayeni, P. Baluk, L.-C. Yao, D. Vossmeyer, G. Zischinsky, G. Zahn, J. Knolle, C. Christner, et al. {alpha}5{beta}1 Integrin Blockade Inhibits Lymphangiogenesis in Airway Inflammation Am. J. Pathol., June 1, 2009; 174(6): 2378 - 2387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Kataru, K. Jung, C. Jang, H. Yang, R. A. Schwendener, J. E. Baik, S. H. Han, K. Alitalo, and G. Y. Koh Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution Blood, May 28, 2009; 113(22): 5650 - 5659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. E. Banziger-Tobler, C. Halin, K. Kajiya, and M. Detmar Growth Hormone Promotes Lymphangiogenesis Am. J. Pathol., August 1, 2008; 173(2): 586 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Halin, H. Fahrngruber, J. G. Meingassner, G. Bold, A. Littlewood-Evans, A. Stuetz, and M. Detmar Inhibition of Chronic and Acute Skin Inflammation by Treatment with a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Am. J. Pathol., July 1, 2008; 173(1): 265 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Roesli, V. Mumprecht, D. Neri, and M. Detmar Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mapping FASEB J, June 1, 2008; 22(6): 1933 - 1944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hos, F. Bock, T. Dietrich, J. Onderka, F. E. Kruse, K.-H. Thierauch, and C. Cursiefen Inflammatory Corneal (Lymph)angiogenesis Is Blocked by VEGFR-Tyrosine Kinase Inhibitor ZK 261991, Resulting in Improved Graft Survival after Corneal Transplantation Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 1836 - 1842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-H. Jeon, C. Jang, J. Han, R. P. Kataru, L. Piao, K. Jung, H. J. Cha, R. A. Schwendener, K. Y. Jang, K.-S. Kim, et al. Profound but Dysfunctional Lymphangiogenesis via Vascular Endothelial Growth Factor Ligands from CD11b+ Macrophages in Advanced Ovarian Cancer Cancer Res., February 15, 2008; 68(4): 1100 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kajiya, R. Huggenberger, I. Drinnenberg, B. Ma, and M. Detmar Nitric oxide mediates lymphatic vessel activation via soluble guanylate cyclase {alpha}1{beta}1-impact on inflammation FASEB J, February 1, 2008; 22(2): 530 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Halin, N. E. Tobler, B. Vigl, L. F. Brown, and M. Detmar VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes Blood, November 1, 2007; 110(9): 3158 - 3167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Baluk, J. Fuxe, H. Hashizume, T. Romano, E. Lashnits, S. Butz, D. Vestweber, M. Corada, C. Molendini, E. Dejana, et al. Functionally specialized junctions between endothelial cells of lymphatic vessels J. Exp. Med., October 1, 2007; 204(10): 2349 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Sundar and T. S. Ganesan Role of Lymphangiogenesis in Cancer J. Clin. Oncol., September 20, 2007; 25(27): 4298 - 4307. [Abstract] [Full Text] [PDF]
|
|
